Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

americanpharmaceuticalreviewNovember 10, 2018

Tag: OncoSec , patient , KEYNOTE-890 , OncoSec

PharmaSources Customer Service